Skip to content

Price / book at other companies

Amgen logo
AmgenAMGN
20.6×-6.3×
Moderna logo
ModernaMRNA
2.7×+1.6×
Royalty Pharma logo
Royalty PharmaRPRX
2.1×+0.7×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×
Incyte logo
IncyteINCY
3.3×+0.1×

Other financials

Income statement

See full
Revenue$2.5M-66.7%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$22.44B+175%
Enterprise value$21.13B+157%
P/S2,716.9×+2,436×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Calculated from Roivant Sciences’s reported figures.

Based on the most recent quarter.

The official record: Roivant Sciences’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's price / book?
Roivant Sciences (ROIV) reported price / book of 4.4× in Q1 2026.
How has Roivant Sciences's price / book changed year-over-year?
Roivant Sciences's price / book increased by 185.1% year-over-year, from 1.5× to 4.4×.
What is the long-term trend for Roivant Sciences's price / book?
Over 4 years (2021 to 2025), Roivant Sciences's price / book has grown at a -1.6% compound annual growth rate (CAGR), from 12.9× to 12.1×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.